Skip to content
Close
SEARCH

How do you substantiate the value of a Lab-of-the-Future investment?

Assessing the Automation and AI potential in future R&D labs

The why

Investing in a Lab-of-the-Future typically requires substantial capital, making it challenging to justify to a CFO. While the benefits of advancing the R&D pipeline faster and with higher-quality outputs are clear, articulating the mechanisms that deliver those benefits is far more complex.

The challenge

Our client planned to significantly expand their R&D activities in the coming years, both by increasing throughput and broadening their portfolio. Although there was strong willingness to invest in new lab facilities, developing a compelling business case proved difficult. Few data points or external benchmarks exist to clearly articulate the impact a Lab-of-the-Future can deliver, making it challenging to substantiate the potential benefits.

How we helped

Biobridge Partners conducted an extensive research effort to understand both the realised impact and the realistic potential of advanced lab automation models. The work included expert interviews with major global pharmaceutical companies, academic institutions, equipment manufacturers, and specialist advisors, complemented by validation across globally available sources. As the findings were triangulated, clear patterns emerged and provided guidance on the potential associated with different automation-maturity archetypes.

Outcome

Across seven maturity levels, the study revealed an overall productivity potential of 25–35%. In addition, several unquantified yet meaningful improvements were also reported. Key benefits of a Lab-of-the-Future are:
5–10x increases in lab throughput
25–40% direct cost savings
35–50% time savings

“This is incredibly insightful. I would like you to make the findings available for the benefit of the Lab-of-the-Future community.”
Client sponsor
12

What moved the needle

Taking a strategic approach to a highly technical question Bringing together scientific closeness and structured strategic thinking to evaluate the business case for the Lab of the Future.
Applying a CFO lens while deeply understanding the scientists behind the experiences Translating expert insights into tangible business case assumptions and value drivers.
Partner

Jens Rommer

Jens is a seasoned strategy advisor with 30 years of experience in management consulting. Former Head of Monitor Deloitte Denmark, he brings deep expertise in shaping corporate agendas, TA strategies, operating model design, digital and AI value creation, and M&A for leading global corporations.

Jens holds an M.Sc. in Electronics Engineering from the Technical University of Denmark and is a certified Master Strategist from Monitor Deloitte.

Selected experience
  • Opportunity assessment for a commercialization partner
  • TA strategy for immunology business
  • Lab of the Future potential and operating model design
  • Performance management in clinical operations
Book meeting
Jens Rommer
Partner

Daniel Schmidt

Daniel works with life science executives to design strategies, operating models, and transformation programs. He brings both functional depth and board-level perspectives, helping senior leaders navigate complexity and make clear choices. He formerly led the life science practice at Deloitte Denmark.

Daniel holds a B.Sc. in International Business and an M.Sc. in Economics and Business Administration from Copenhagen Business School.

Selected experience
  • TA strategy for immunology portfolio
  • Strategy for application and value realisation of AI across R&D
  • Business model design for new innovative business unit
  • Global digital transformation across commercial functions
Book meeting
Daniel Schmidt